Who Is Todd Shapiro? Chief Executive Officer and Director, Rhelion Life Sciences
Chief Executive Officer and Director of Rhelion Life Sciences.
Todd Shapiro is the Chief Executive Officer and a Director of Rhelion Life Sciences.
At Mind Medicine Law, we track the people building legal, evidence-based access to psychedelic medicine: the companies running the trials, the researchers and advocates behind them, and the officials who write and run the laws.
Shapiro previously served as Chief Executive Officer and Director of Red Light Holland Corp. and stated that the acquisition of Filament Health fundamentally changed the identity of the company.
Where Todd Shapiro Is Now
- Current role: Chief Executive Officer and Director
- Organization: Rhelion Life Sciences
- Known for: Leading Rhelion Life Sciences and previously serving as Chief Executive Officer and Director of Red Light Holland Corp.
- Recent news: Stated that Dr. Robin Carhart-Harris's guidance and network would assist in supporting more researchers with standardized natural psilocybin and potentially with clinical trial development.
Todd Shapiro currently serves as the Chief Executive Officer and a Director of Rhelion Life Sciences.
Executive Leadership and Red Light Holland
Todd Shapiro served as Chief Executive Officer and Director of Red Light Holland Corp. He stated that fiscal 2026 was focused on building a foundation and moving from underground to mainstream rather than maximizing short-term revenue.
Shapiro stated that over the past year, the company simplified its operating portfolio, exited misaligned businesses, strengthened its balance sheet, and concentrated capital on value-creating opportunities The Globe and Mail.
Filament Health Acquisition and Collaborations
Shapiro stated that the acquisition of Filament Health fundamentally changed the identity of the company The Globe and Mail. He noted that Filament's original scientific achievements serve as the foundation while new leadership evolved to maximize their commercial and strategic value.
Regarding scientific collaborations, Shapiro stated that Dr. Robin Carhart-Harris had been a trusted voice since first joining the company, noting: 'Robin has been a trusted voice for us since he first joined, and we are very happy to have him with us again' FinanzNachrichten.de. Shapiro also stated that with Filament as part of Rhelion, Dr. Robin Carhart-Harris's guidance and network would assist in supporting more researchers with standardized natural psilocybin and potentially with clinical trial development.
Strategic Mission and Industry Outlook
Shapiro stated that Rhelion Life Sciences' mission is to responsibly advance naturally derived psychedelic medicines through rigorous science, disciplined execution, and strategic partnerships The Globe and Mail.
According to Shapiro, the company combines one of the industry's largest naturally derived psychedelic IP portfolios with GMP manufacturing, regulatory expertise, completed Phase I development, Phase II-ready programs, and an international scientific network The Globe and Mail. Shapiro also stated that psychedelic medicine is entering a new era and that Rhelion is built to help lead it.
Frequently asked questions
Who is Todd Shapiro?
Todd Shapiro is the Chief Executive Officer and a Director of Rhelion Life Sciences, and previously served as Chief Executive Officer and Director of Red Light Holland Corp.
What is the stated mission of Rhelion Life Sciences?
Todd Shapiro stated that Rhelion Life Sciences' mission is to responsibly advance naturally derived psychedelic medicines through rigorous science, disciplined execution, and strategic partnerships.
What did Todd Shapiro say about the acquisition of Filament Health?
Todd Shapiro stated that the acquisition of Filament Health fundamentally changed the identity of the company, and that Filament's original scientific achievements serve as the foundation while new leadership evolved to maximize their commercial and strategic value.
What did Todd Shapiro state regarding Dr. Robin Carhart-Harris?
Todd Shapiro stated that Dr. Robin Carhart-Harris had been a trusted voice since first joining the company, and that with Filament as part of Rhelion, his guidance and network would assist in supporting more researchers with standardized natural psilocybin and potentially with clinical trial development.
What portfolio assets does Rhelion Life Sciences hold according to Todd Shapiro?
Todd Shapiro stated that the company combines one of the industry's largest naturally derived psychedelic IP portfolios with GMP manufacturing, regulatory expertise, completed Phase I development, Phase II-ready programs, and an international scientific network.
What contact details are available for Todd Shapiro?
Todd Shapiro's email address is todd@rhelion.com, and he provided the telephone number 647-204-7129 for inquiries regarding Rhelion Life Sciences.
Sources
General information compiled from the public reporting cited above, not medical or legal advice. Mention of a treatment, trial or bill is not a claim that it is safe, effective or legal where you live. Not endorsed by or affiliated with Todd Shapiro or Rhelion Life Sciences. See more people in psychedelic medicine.